Literature DB >> 18546626

Ovarian cancer: can we reverse drug resistance?

David S P Tan1, Joo Ern Ang, Stan B Kaye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18546626     DOI： 10.1007/978-0-387-68969-2_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  5 in total

1.  Maternal predictors of neonatal anthropometric measurements in the Sultanate of Oman.

Authors:  Reem M Abdulrahim; Ahmed Babiker Idris; Mohamed Abdellatif; Asad Ur-Rahman; Nigel Fuller
Journal:  Sudan J Paediatr       Date:  2022

2.  Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Authors:  Fiona Furlong; Patricia Fitzpatrick; Sharon O'Toole; Sine Phelan; Barbara McGrogan; Aoife Maguire; Anthony O'Grady; Michael Gallagher; Maria Prencipe; Aloysius McGoldrick; Paul McGettigan; Donal Brennan; Orla Sheils; Cara Martin; Elaine W Kay; John O'Leary; Amanda McCann
Journal:  J Pathol       Date:  2012-01-17       Impact factor: 7.996

3.  Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.

Authors:  Y Wang; Q Sheng; M A Spillman; K Behbakht; H Gu
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

4.  Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas.

Authors:  Harsh Vardhan Jain; Alan Richardson; Michael Meyer-Hermann; Helen M Byrne
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

5.  Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma.

Authors:  Xiaoping Song; Kailv Sun; Jianming Hu; Jianghu Zhou
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.